Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...

Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...